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DEFINITION OF CHRONIC LEUKEMIA 
C HRONIC leukemias have been defined as “those leukemias with an ex- pected duration of life of one to twenty years or more, average three to five 
years . . . from the onset of the first symptoms. . . . The most differentiated 
stage of the involved series is always present, in addition to the less differentiated 
cells.“’ Because of the increasing frequency of therapeutically induced re- 
missions in acute leukemia, the distinction of the chronic forms on a temporal 
and prognostic basis has less significance than formerly. Nevertheless, in spite 
of overlapping of survival times, the great majority of patients with chronic 
leukemia live much longer than those patients with the acute forms of the disease 
who experience most nearly complete remissions. 
CLASSIFICATION 
Proliferation of cells of the granulocytic or lymphocytic series characterizes 
most cases of chronic leukemia, and, in addition to their numerical importance, 
these forms merit preferential consideration because, as a rule, they may be well 
controlled by specific treatment. However, in the category of chronic leukemia 
there must also be placed some variants of myeloid and reticuloendothelial 
disease which are difficult to classify and are usually characterized by anemia 
and leukopenia, as well as by the presence of small numbers of atypical and 
poorly ,differentiated cells in peripheral blood and bone marrow. These proc- 
esses frequently terminate in acute phases with rising leukocyte counts con- 
sisting of highly anaplastic cells. Such terms as “preleukemic myelopathy,” 
“aleukemic myelosis,” “malignant reticulosis,” and “aleukemic monocytic 
leukemia” have been applied to this group of conditions. 
It is sometimes difficult to delineate precisely the differences between leu- 
kemia and instances of chronic “nonleukemic” myeloproliferative disease, in- 
cluding some cases of polycythemia vera and agnogenic myeloid metaplasia. 
However, there should be little room for disagreement in classifying the great 
majority of cases of chronic leukemia and it is this group with which we are 
primarily concerned. 
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ETIOLOGIC CONSIDERATIONS 
Since it is not possible to discuss measures designed to prevent or cure the 
leukemic disorders, the attention of epidemiologists and clinicians is necessarily 
restricted to consideration of factors which may have a bearing on the etiology 
or at least the occurrence of these conditions, and to evaluation and comparison 
of therapeutic agents and treatment regimens. 
The relationships of geographical location, race, sex, and age to the incidence 
of the various types of leukemia and the relative frequencies of these types have 
little direct bearing on the etiology of the leukemias unless there can be shown 
a trend in incidence or a changing pattern of cytologic and clinical characteristics. 
If such changes can be convincingly documented it becomes significant to search 
for environmental factors which might appropriately be correlated with the 
occurrence of leukemias of specific types and with a relative propensity to affect 
particular segments of the population. Unfortunately, no meaningful corre- 
lations have so far been described, except that between exposure to ionizing 
radiation and the subsequent development of 1eukemia.2-4 
INCIDENCE AND RELATIVE FREQUENCY 
Mortality statistics reveal a progressive rise in the incidence of leukemia 
since 1900.5 This increase cannot be accounted for, in the main, by an aging 
population nor by improved diagnostic facilities. Because available mortality 
statistics obtained in successive years on large unselected populations give no 
information on cell types or classification on basis of acuity or chronicity, it has 
generally been necessary to obtain such data from restricted groups and in par- 
ticular from hospital case series. The latter, in spite of a high degree of selection, 
have the advantage, if carefully studied, of uniform criteria of diagnosis and 
classification. 
In 1942 and 1943, the author reported a series of cases of Ieukemia seen at 
the Simpson Memorial Institute of the University of Michigan from mid-1927 
through the end of 1941, a period of 14% years.6z7 It may be of interest to 
compare some of the data for that period with the equivalent information for 
cases of leukemia observed during the period of 1942 to 1956 inclusive. Com- 
parisons of sex, age, and type of leukemia should not be affected materially by 
influences tending to promote selection provided certain precautions are taken. 
Because of lack of uniform coverage of childhood cases of leukemia, all children 
under 14 years of age have been excluded from the study and the earlier series 
has been re-evaluated with omission of children. The diagnostic complexity 
of the earlier reports has been simplified so that only broad categories are con- 
sidered, thus eliminating, it is believed, the danger of establishing differences 
which are merely the result of changes in diagnostic criteria. This also makes 
comparisons with other reports more feasible. The classifications employed 
are : (1) chronic granulocytic leukemia, which includes cases formerly listed 
as chronic myelocytic and chronic myelomonocytic; (2) chronic lymphocytic 
leukemia, which comprises cases formerly reported as chronic lymphogenous 
and chronic lymphosarcoma cell; (3) chronic monocytic leukemia, which was 
designated as chronic histiomonocytic in the earlier report and includes both 
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leukemic and subleukemic forms of malignant reticuloendotheliosis; (4) acute 
leukemia, which comprises all cases which come within the definitions of acute 
or subacute leukemias, as recommended by the Committee for Clarification of 
the Nomenclature of Cells and Diseases of the Blood and Blood-forming Organs.’ 
The incidence in the two time periods of the several types of leukemia and 
the sex distributions and median ages for the chronic forms of leukemia are shown 
in Tables I and I I. 
TABLE I. THE NUMBER OF CASES AND THE REWTIVE FREQUENCY OF THE CHRONIC FORMS OF LEUKEMIA ND OF 
ACUTE LEUKEMIA IN Two CONSECUTWE 15-YEAR PERIODS 
- 
PERIOD 
NTJM- PER NUW PER NUM- PER NW- 
BER CENT BER CENT BER CENT BER 
__~ __-_____-- _____ 
(1) 1927-1941 131 30.7 150 35.1 16 3.7 130 
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TABLE II. THE SEX DISTRIBUTION AND MEDIAN AGES FOR THE CHRONIC FORMS OF LEUKEML~ IN Two CONSECUTIVE 
15-YEAR PERIODS 
NuMBER OF CASES PERCENTOFTOTAL CASES PERCENTMALES MEDZANAGE 
Lymphocytic 131 187 318 44.1 42.8 43.3 62.4 66.6 64.8 63 64 64 
_I--- -------- 
Granulocytic 150 224 374 50.5 51.3 51.0 52.9 52.7 52.7 46 44 45 
_F___-______ -~--~__- 
Monocytic 16 26 42 5.4 5.9 5.7 87.5 80.8 83.3 45 48 47 
From the data presented, two general conclusions, one of a positive and 
the other of a negative nature, seem warranted. First, the occurrence of acute 
leukemia in adults in proportion to the number of cases of chronic leukemia of 
all types appears definitely to be on the increase. During the period 1927 to 
1941 the ratio of adult cases of acute leukemia to those of chronic leukemia was 
0.44, whereas for 1942 to 1956 it was 0.77 in spite of a substantial increase in 
the number of cases of chronic leukemia. A further chronologic breakdown, 
which will be reported elsewhere, provides additional strong support for the 
growing incidence of acute as contrasted with chronic leukemia, since there is 
revealed a sustained trend with a present ratio of acute to chronic leukemia of 
about 1.0. 
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The second conclusion to be drawn from the case records of the two periods 
is that no evidence is afforded of a significant change in the sex or age incidence 
of chronic leukemia or of an alteration in the relative frequencies of the three 
types of chronic leukemia under consideration. No inference concerning over- 
all increase in chronic leukemia-isjustified since, although in terms of total 
hospital registrations the number of cases of chronic leukemia has increased, it 
is not possible to weigh accurately factors which affect the referral of patients 
with a particular disease to a medical center. 
These findings, therefore, do not support the suggestion of a shift in the sex 
ratio in recent years toward a higher proportion of females with chronic granulo- 
cytic leukemia8 nor of a change in relative frequency of chronic lymphocytic 
and chronic granulocytic leukemia favoring the former.g 
THERAPEUTIC CONSIDERATIONS, THE DECISION TO INSTITUTE 
OR WITHHOLD TREATMENT 
A much greater variety of clinical manifestations and a broader range of 
hematologic changes characterize chronic lymphocytic leukemia than is true 
of the granulocytic type. It is this lack of homogeneity of the lymphocytic 
form of the disease that provides grounds for prognostic differentiation and cri- 
teria for the selection of antileukemia therapy or deferral of specific treatment. 
When a new case of chronic granulocytic leukemia is under consideration 
there is usually little to indicate whether the disease is likely to run its course 
in one year or three or six. Th e c h oice of treatment will depend on the interest 
of the physician, or on extraneous factors such as availability of a particular 
medication or ease of follow-up examinations, except that in an occasional pa- 
tient severity of pressure manifestations from a greatly enlarged spleen may 
determine the decision to employ x-radiation over the splenic region. In the 
patient whose granulocytic disease is discovered as an incident of medical evalu- 
ation for an unrelated condition or during a health examination, specific therapy 
may be postponed until symptoms develop. There is no evidence that later 
control of the disease or length of survival is adversely affected by such deferment. 
However, in almost every instance, the disease progresses during the interval of 
no therapy, and omission of treatment is rarely feasible for longer than a few 
months. It is largely for this reason that many clinicians,including the writer, 
institute specific therapy for chronic granulocytic leukemia as soon as the diagno- 
sis is made. The advantages of so doing are partly psychological, with strength- 
ening of the physician-patient relationship, greater assurance of cooperation, 
and avoidance of the disheartening and sometimes confidence-losing effect which 
many patients experience when they are told after a short period of observation 
that their disease has entered a new phase requiring treatment with radiation 
or drugs. 
The situation with respect to therapy for chronic lymphocytic leukemia 
is quite different. Here there may be no signs of progress of the disease for 
many months or even years. Since the success of all specific treatment of leu- 
kemia depends upon the establishment of a patient-disease (? host-tumor) re- 
lationship favoring the former, there seems to be no justification for interfering 
when such a favorable relationship already exists. 
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When confronted with a case of chronic lymphocytic leukemia in which the 
patient is without symptoms attributable to the disease, anemia or thrombocy- 
topenia are not present, and the leukocyte count, although elevated, is not 
progressively rising, it is the writer’s practice to advise the patient that a period 
of observation is desirable before deciding on a management regimen. This 
waiting period, with re-evaluation at intervals at first of 2 months, later as long 
as 6 months, may be prolonged indefinitely. An illustration is provided by a 
man, now aged 63 years, who has been observed by the writer for 12 years. The 
diagnosis of chronic lymphocytic leukemia was made in 1945, no treatment has 
ever been given, and there are no signs of progress of the disease. There are 
small, soft lymph nodes in cervical and axillary regions, and for the past 5 years 
the spleen has been felt 2 to 3 cm. below the costal margin. The total leukocyte 
count is usually between 15,000 and 20,000 per cubic millimeter and the lympho- 
cytes, mostly small and well differentiated, range between 60 per cent and 80 
per cent. It may be objected that this is not a case of leukemia but some form 
of benign lymphocytosis. Perhaps so, but there appears to be no way of making 
such a distinction, except in retrospect, nor can this patient be assured that his 
disease will never enter a phase requiring antileukemia therapy. 
OBJECTIVES OF THERAPY 
The two major objectives of specific as opposed to supportive therapy in 
chronic leukemia are (1) attack on the systemic disease, with elimination or 
at least diminution of such manifestations as anemia, tendency to hemorrhage, 
thrombosis and infarction, unusual susceptibility to infection, fever, and weight 
loss; and (2) relief of effects caused by local tumefaction exerting pressure, 
compression, and obstruction, or by particular organ or tissue infiltration pro- 
ducing functional changes. 
Therapy directed toward particular lesions is essentially limited to locally 
applied radiation with surgical procedures occasionally indicated. In this 
connection, resection of the spleen in leukemia is rarely justifiable even in the 
presence of secondary “hypersplenic” hemolytic anemia or thrombocytopenia, 
since such manifestations can usually be well controlled with moderate sized 
doses of the corticosteroids. However, some patients with chronic lymphocytic 
leukemia require increasing amounts of these hormones, exceeding limits of 
tolerance, and in such situations splenectomy may be of great benefit. In granu- 
locytic leukemia removal of the spleen is characteristically followed by rapid 
enlargement of the liver and refractoriness to all available forms of therapy. 
Measures available for systemic treatment of chronic leukemia will receive 
individual consideration and will be discussed in relation to the various types 
of the disease. 
CHEMOTHERAPT IN CHRONIC LEUKEMIAS 
Although drug therapy of leukemia, namely with inorganic arsenic as Fow- 
ler’s solution, or with benzol, has a long history, the management of patients 
with chronic leukemia was for many decades almost exclusively within the 
province of the radiologist. 
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The introduction of a number of new chemical agents for the treatment of 
leukemia and lymphoma during the past decade has provided the clinician with 
a choice of therapeutic methods and has placed upon him a corresponding degree 
of responsibility not only for wise selection but, of even greater importance, for 
familiarity with the general properties and potentialities of the drugs he uses, 
and for careful individualized follow-up evaluation of his patients. 
Interest in the novel is understandable and every new type of agent capable 
of affecting the course of leukemia should receive critical evaluation. But for 
a drug to compete successfully for a place in the therapy of leukemia it should 
be at least as effective in terms of adequacy of control and mean survival as 
existing methods of treatment, or it should possess unique properties which 
render it preferable in special situations. 
Of the drugs found to be effective in chronic leukemias, arsenic and benzol 
are not of contemporary interest. There remain for consideration urethan, 
deacetylmethyl-colchine (Colcemide, Demecolcin), the antimetabolites (es- 
sentially limited to 6 mercaptopurine, Purinethol and its analogues), and certain 
polyfunctional alkylating agents. 
Much effort is currently being spent by cooperating clinical groups through- 
out the United States on the comparative evaluation of chemical agents in the 
treatment of leukemia and other forms of disseminated neoplastic disease. The 
rigidity of the criteria for case selection, folIow-up, and measurement of response, 
and the statistical analyses required, should yield much useful information, es- 
pecially in the matter of dosage schedules and the possible merits of combination 
and sequential therapy. Furthermore, the experience gained from the prepa- 
ration and application of protocols and the pooling of observations by a number 
of cooperating clinical investigators will undoubtedly prove immensely valuable 
in the evaluation of new agents. However, sufficient experience, even though 
not carefully controlled, has already been gained to render it unlikely that the 
conclusions to be drawn from the statistically superior data collected by the 
cooperating groups will result in any general or major change in the currently 
held views on therapeutic agents which are presently available. 
RADIATION THERAPY 
The standard of reference for chemotherapy of chronic leukemia is ionizing 
radiation, yet radiation has been employed in a variety of ways, such as regional 
x-ray therapy (usually to spleen or enlarged lymph nodes) or total body exposure, 
intensive dosage short courses or prolonged periods of low dose administration. 
Radiation has been by x-ray and by internal radioisotope therapy, usually ad- 
ministered as radioactive phosphorus (P”‘). According to Tivey,‘O who analyzed 
survival figures for a large number of patients with granulocytic or lymphocytic 
leukemia reported in the literature through 1951, there is no difference between 
the survival prospects in the two forms of leukemia, and half the patients in any 
series comparably treated may be expected to survive for 2.65 years after the 
development of symptoms or 1.6 years after commencement of therapy. Tivey 
applied the same analytical techniques to a series of cases of chronic granulocytic 
and lymphocytic leukemia treated by Osgood with regularly spaced P32 or total 
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body roentgen irradiation in doses designed to maintain the leukocyte count 
between 10,000 and 20,000 per cubic millimeter.” He concluded that in this 
series a survival of half the patients for 4.8 years from the onset of symptoms 
could be predicted. Of course, other factors than specific therapeutic metho- 
dology enter into comparisons of this sort, especially the extent to which the 
principle of total patient care is applied and the recent advances in blood trans- 
fusion therapy, control of intercurrent infections, and management of hemorrhage 
and secondary hemolytic disease. Nevertheless, it is the writer’s opinion that 
continued even control of the leukemic process as long as possible not only pro- 
motes a sense of well-being in patients so treated but also results in increased 
survival times. 
CHRONIC GRANULOCYTIC LEUKEMIA 
Since 1940, the following agents other than x-radiation have been used at 
the Simpson Memorial Institute in the therapy of chronic granulocytic leukemia: 
radioactive phosphorus, 87 cases; urethan, 36 cases; triethylene melamine (TEM), 
41 cases; l-4, dimethanesulfonyloxybutane (Myleran), 31 cases; and deacetyl- 
methylcolchicine (Colcemide), 7 cases. In addition, a few patients have received 
in clinical trials drugs no longer used for this purpose, and a number of patients 
with advanced granulocytic leukemia not responsive to the agents listed above 
have received 6-mercaptopurine (Purinethol), or another antipurine. 
For systemic therapy in chronic granulocytic leukemia, total body x-radi- 
ation and radioactive phosphorus (P”‘) have been almost completely replaced 
in recent years in our institution by the two chemically unrelated alkylating 
agents, Myleran and TEM. 
Irradiation, usually in the form of P32, is employed when frequent follow-up 
examinations and blood counts (as a rule every 2 to 4 weeks) are not feasible. 
The usual initial dose of Pi2 is from 4 to 8 mc. administered intravenously de- 
pending on the size of the patient and the evidences of activity of the disease. 
The patient is seen in 6 to 9 weeks when a second dose of 2 to 4 mc. intravenously 
may be given if satisfactory control has not been obtained. Subsequent return 
visits may be extended to 3- to 6-month intervals. It must be stated, however, 
that in the writer’s view interval therapy of chronic granulocytic leukemia based 
on recurrence of signs of activity does not provide as satisfactory control as the 
regularly spaced administration of radiation as advocated by Osgood,” or the 
continued use of a chemotherapeutic agent. 
It is recognized that an occasional patient with chronic granulocytic leukemia 
will enter prolonged remission after a single course of x-ray therapy, one dose of 
radioactive phosphorus, or a period of drug administration. An example of 
such responses is provided by a woman first seen by the writer in May, 1952, 
at the age of 39 years. She complained of fatigability, nervousness, and dis- 
comfort in the left upper quadrant of 8 months’ duration. The spleen descended 
7 cm. below the left costal margin and the liver was moderately enlarged. The 
leukocyte count was 76,000 per cubic millimeter with a differential count charac- 
teristic of chronic granulocytic leukemia. The hemoglobin value was 11.5 Gm. 
per 100 C.C. and the platelet count was elevated. Sternal marrow aspiration 
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provided a highly cellular specimen with granulocytic hyperplasia and striking 
increase in progranulocytes and myelocytes. The M :E ratio was 1O:l and 
megakaryocytes were extremely numerous. After 2% months of observation 
without treatment, the leukocyte count had increased to 99,000 with myelo- 
blasts 4 per cent, progranulocytes 4 per cent, myelocytes 7 per cent, metamyelo- 
cytes 21 per cent, band neutrophils 18 per cent, segmented forms 38 per cent, 
eosinophils 1 per cent, lymphocytes 5 per cent, and monocytes 2 per cent. Radio- 
active phosphorus was administered intravenously in a single dose of 7.6 mc. 
Remission occurred promptly and has continued without any form of treatment 
up to the time of reporting. When last seen in March, 1957, nearly 5 years 
after her first visit, she was asymptomatic and the spleen tip was felt just at the 
costal margin on deep inspiration. The leukocyte count was 6,150 and the hemo- 
globin value 13.2 Gm. A few immature granulocytes were observed on the 
stained blood film, but the most striking abnormality was a basophil count of 
21 per cent. Platelets were very numerous. Remissions such as this in chronic 
granulocytic leukemia, although rarely of such long duration, are sufficiently 
frequent to render it hazardous to base comparisons of intermittent versus 
continued therapy on small numbers of cases treated by either method. 
Urethan (ethyl carbamate) was shown by Paterson and her associates,‘2 
in 1946, to have effects in chronic leukemia comparable to those obtained with 
x-ray therapy. Urethan found a place in the treatment of chronic granulocytic 
leukemia because of its ease of administration and relative freedom from pro- 
duction of rapid severe bone marrow depression. Thrombocytopenia is not 
produced, but in patients receiving prolonged medication with urethan, pro- 
found leukopenia sometimes develops. 
Urethan reached the peak of its popularity at the Simpson Memorial Insti- 
tute in 1947, 1948, and 1949. During those years 29 cases of chronic granu- 
locytic leukemia received initial therapy with urethan. Of the total of 36 cases, 
6 of whom had been treated previously with radiation and one with Fowler’s 
solution, 13, or 36 per cent, obtained remissions which were classified as “excel- 
lent” or “good,” as defined later; 17, or 47 per cent, had only fair responses; and 
6, or 17 per cent, received little or no benefit from urethan even though the status 
of their disease was not far advanced when treatment was begun. Conceding 
that the small sizeof this series precludes generalizations concerning the effective- 
ness of urethan, it is nevertheless probably significant that in only 13 of 36 cases, 
none of them far advanced when treated, was there reasonably good control of 
the disease for 4 months or longer. 
Even before newer drugs became available, enthusiasm for the use of urethan 
in chronic granulocytic leukemia was on the wane since it became increasingly 
evident that control was not as readily maintained with this drug as with ionizing 
radiation. 
The most promising compounds so far used in the treatment of chronic 
leukemia and lymphoma are those possessing alkyl groups which are capable 
of reacting chemically with constituents of the nuclei of proliferating cells and 
so exerting cytotoxic effects, especially on growing cells of the hemic and lym- 
phatic systems and the epithelial cells of the alimentary tract. These alkylating 
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agents exist in a wide variety of chemical structures of which two classes, the 
nitrogen mustards and the sulfonic acid esters, have found most extensive ap- 
plication in medicine. 
“Nitrogen mustard” (methyl&s (fl-chloroethyl) amine hydrochloride, 
HN2, Mustargen) was the first alkylating agent to be introduced into cancer 
chemotherapy.13 This drug, even in the early days of its use, did not receive 
wide acceptance in the treatment of chronic leukemia, for reasons which are 
not entirely clear, but which probably have to do in part with the recommended 
dosage. The usual dose of HN2 per course of treatment is stated to be 0.4 mg. 
per kilo given intravenously generally in four divided amounts on consecutive 
or alternate days followed by an interval before the next treatment of at least 
6 weeks. This amount, ranging between 20 and 30 mg. for most adults, is, in 
general, much too small for patients with chronic granulocytic leukemia and too 
large for many of those with chronic lymphocytic leukemia. There is no reason 
to conclude that HN2 would not prove to be as valuable as TEM, which we have 
shown to be as effective as Myleran in the treatment of chronic granulocytic 
leukemia, provided that a judicious plan of administration were employed which 
would yield adequate treatment to achieve the desired result without serious 
risk of overdosage. HN2 does, however, possess the drawbacks of requiring 
especially careful intravenous administration and of producing acute nausea 
and vomiting. The latter effects can largely be obviated by the prior adminis- 
tration of 25 or 50 mg. chlorpromazine, followed by a second dose 3 hours after 
HN2 administration. 
Demonstration of the human antitumor activity of triethylene melamine 
(TEM), in 1950, by Rhoads and others14 was followed by extensive application 
of this drug to the treatment of leukemia and lymphoma. From these clinical 
trials there emerged the general impression that, in respect to leukemia, TEM 
was of greatest usefulness in the chronic lymphocytic form of the disease, in 
spite of adequate documentation of its effectiveness in chronic granulocytic 
leukemia.r5 The similarity in chemical structure between HN2 and TEM, as 
polyfunctional alkylating agents, undoubtedly was instrumental in suggesting 
the major indications for use and the mode of therapy of the latter drug; namely, 
emphasis on the lymphoid rather than myeloid neoplasms, and the preference 
for intermittent courses of administration rather than continued therapy. 
Therefore, when Myleran was reported to be effective in chronic granulocytic 
leukemia,16 its different chemical structure from the mustards seemed to explain 
the supposed preferential action of Myleran on myeloid and of HN2 and TEM 
on lymphoid proliferative disease. On the contrary, the only demonstrable 
differences in biologic action between the two classes of alkylating agents are of 
a quantitative rather than qualitative nature and have to do with rates of ab- 
sorption, diffusion into cells, and chemical reactivity.17 
At the Simpson Memorial Institute 41 patients with chronic granulocytic 
leukemia were treated with TEM during the years 1951 to 1956, and 31 patients 
were treated with Myleran between 1953 and 1956. Some of these patients had 
received other medication, such as radiation, urethan, or Colcemide prior to 
being placed on TEM or Myleran. Some were in a relatively early well-dif- 
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ferentiated stage of their disease whereas in others the disorder was advanced 
and many of the granulocytes in the peripheral blood were immature. In this 
category are placed cases of far-advanced disease, with predominance of myelo- 
blasts and atypical progranulocytes in blood and marrow, as well as cases of 
moderately advanced disease, since the distinction between such degrees of se- 
verity is arbitrary and often will vary among different clinicians. On the other 
hand, there is rarely disagreement over classifying a case in the early well-dif- 
ferentiated stage. The patients were classified in terms of the quality and 
duration of their therapeutic responses according to the following criteria. Ex- 
cellent : leukocyte count less than 15,000 per cubic millimeter with early granu- 
locytes (myeloblasts through metamyelocytes) below 5 per cent; normal hemo- 
globin and volume of packed red cells; free of symptoms referable to leukemia; 
spleen not palpable or barely palpable; duration in this status 6 months or longer. 
Good : leukocyte count less than 50,000 with early granulocytes below 20 per 
cent; hemoglobin above 11 Gm. or volume of packed red cells above 30 per cent; 
virtually asymptomatic; splenomegaly less than before treatment; duration in 
this status or better 4 months or longer. Fair: leukocyte count and early 
granulocyte percentage reduced below pretreatment levels; hemoglobin and 
volume of packed red cells essentially stable; no serious incapacitation; duration 
in this status or better 2 months or longer. Poor: disease not under hemato- 
logic or clinical control; serious incapacitation; duration in this status indeter- 
minate. 
TABLE III. CHRONIC GRANULOCYTIC LEUKEMIA TREATED WITH TRIETHYLENE MELAMINE 
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Total 41 2 8 20 
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*Included in cases receiving prior intermittent treatment. 
fThese categories include 4 duplications. resulting from 8ome patients receiving both intermittent 
and continuous therapy. 
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Summaries of our therapeutic experience with triethylene melamine and 
Myleran are presented in Tables III and IV. The TEM and Myleran groups 
are not strictly comparable because the agents became available at different 
times and there was a tendency to employ TEM, in the early period of its use, 
in cases which were becoming difficult to control with radiation or urethan, 
whereas Myleran was introduced as an effective form of therapy for chronic 
granulocytic leukemia and was used from the outset as initial treatment for 
many patients with this disease. Thus of the 41 cases of chronic granulocytic 
leukemia treated with TEM 10 are classified as early and 31 as advanced, 9 had 
had no previous treatment, and 32 had received earlier therapy, whereas of the 
31 cases treated with Myleran 16 are described as early and 15 as advanced, 12 
had had no prior antileukemia medication, and 19 had been previously treated. 
These differences between the two groups of patients, coupled with the fact that 
some time elapsed after TEM was introduced before the importance of continuous 
therapy was appreciated, are probably sufficient to explain the apparently su- 
perior results obtained with Myleran as shown by 8 excellent and 18 good re- 
sponses in contradistinction to the 2 excellent and 15 good responses obtained 
with TEM. 
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Underlined values are usual doses and time periods. 
*Prior intermittent treatment. 
iThese categories include 10 duplications, resulting f’rom some patients receiving both intermittent 
and continuous therapy. 
The collective recorded experience of many clinics supports the conclusion 
that Myleran is an effective and exceedingly useful agent for the treatment of 
chronic granulocytic leukemia. The longest experience is that of the Chester 
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Beatty Research Institute as reported by Galton. He has presented data on 
42 cases of chronic granulocytic leukemia treated with Myleran and on 3 in which 
the analogue dimethyl-Myleran was used. Small initial doses (65 mcg.per kilo- 
gram) were found to be as effective as larger amounts in inducing symptomatic 
relief and increase in hemoglobin, but the larger doses were followed by more 
rapid decline in the leukocyte count and regression in spleen size. Continuous 
therapy was used in 25 cases and was found to be especially useful when the 
leukocyte count rose rapidly after completion of a course of therapy. Main- 
tenance doses ranged between 0.5 and 2.0 mg. daily. It has been found that 
maintenance dosage must be increased with the passage of time, usually as in- 
crements of 0.5 mg. per day every 6 to 8 months. 
In common with other observers Galton found bone marrow aplasia to be 
the only serious toxic effect of Myleran. Such an event was observed twice in 
his series. One patient received unusually large doses and the other continued 
taking small doses without supervision. Other side effects in patients receiving 
Myleran include amenorrhea, minor degrees of pigmentation of the skin, and 
occasionally gynecomastia. 
Galton reported that 34 of his patients were dead and the median survival 
from the time of diagnosis was 36 months compared with 26 months in a group 
of 33 patients treated with radiotherapy alone before 1950. Assuming that the 
time of diagnosis was also the time when therapy was begun, a survival of 50 
per cent of patients with chronic granulocytic leukemia for 3 years compares 
favorably with the longest survival figures previously reported, namely, those 
of Osgood and Seamani as analyzed by Tivey.‘O However, it should not be 
inferred that the evidence as yet is conclusive that Myleran is superior to x-radi- 
ation or radioactive phosphorus in the treatment of chronic granulocytic leukemia. 
It does appear warranted to regard Myleran as at least equal to radiation in 
therapeutic effectiveness and as having other advantages, including ease of 
administration and dosage control, which render it the preferred form of therapy 
for the majority of patients with this disease. 
Colcemide or Demecolcin, like colchicine, owes its cytostatic properties to 
mitotic inhibition with blocking at the metaphase. However, Colcemide is 
some 30 times less toxic, with respect to gastrointestinal manifestations, than 
colchicine, and consequently may be given in relatively large doses and for long 
periods of time. Colcemide was first used in the treatment of chronic granulo- 
cytic leukemia by Moeschlin and his associates,20 and Moeschlin later reported 
observations on 30 patients extending over a period of 3% years with generally 
favorable resultszl An initial dosage of 4 mg. of Colcemide daily, divided into 
two doses given orally morning and evening, is recommended. A few patients 
required doses as high as 10 mg. daily. As soon as the leukocyte count has 
fallen to a level of 30,000 per cubic millimeter, Moeschlin recommends that 
the medication be discontinued for 3 or 4 days and then resumed in maintenance 
dosage, which is usually about one-third of the initial level, but must be adjusted 
to individual requirements. 
Our limited experience with Colcemide in the treatment of chronic granu- 
locytic leukemia has led us to the conclusion that the effects of this drug are less 
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dependable than those of Myleran or TEM, that the dosage is harder to regulate, 
and that unpleasant, but not serious side effects, are more common. These 
include digestive symptoms and alopecia. The major and perhaps the only 
indication for Colcemide in the treatment of leukemia is, as Moeschlin empha- 
sizes, in the proliferative and poorly differentiated phase which many patients 
with chronic granulocytic leukemia enter during the terminal period of their 
illness. Moeschlin has reported favorable responses in 3 of 5 patients with 
terminal myeloblastic transformation. The experience of others in this con- 
nection has been varied, but on the basis of the small number of cases reported 
it appears justifiable to conclude that, although any great benefit is unlikely, 
Colcemide is worthy of a trial when radiation and the alkylating agents, Myleran 
and TEM, no longer effectively control proliferation of cells in chronic granu- 
locytic leukemia. 
There remains to be considered the place of metabolic antagonists in the 
treatment of chronic granulocytic leukemia. The 4-amino analogues of pteroyl- 
glutamic acid or “anti-folics” (methotrexate and Aminopterin) were found to 
produce temporary improvement in most cases of early granulocytic leukemiaz2 
but the development of severe toxic manifestations during the course of treat- 
ment precludes their use in this condition. Patients with advanced granulocytic 
leukemia have only rarely been even temporarily benefited by compounds of 
this class. The place of the antipurine, Gmercaptopurine (Purinethol), is some- 
what more favorable. The collective experience of a number of clinical investi- 
gators23 attests to the efficacy of this drug in most cases of early chronic granu- 
locytic leukemia. However, the disorder is not as well controlled with this 
agent as with Myleran or TEM and relapse almost invariably occurs as soon 
as the medication is discontinued. There is a place, however, for Purinethol 
administered by mouth in a daily dose of 2 to 3 mg. per kilo in the advanced stage 
of granulocytic leukemia when it may effectively suppress for a time leukemic 
cell proliferation even though the disease has become unresponsive to radiation 
and the alkylating antileukemia agents. 
CHRONIC LYMPHOCYTIC LEUKEMIA 
The great variability in the clinical course and response to treatment, as 
well as the indications for therapy in chronic lymphocytic leukemia, make it 
unrealistic to attempt to establish the preferred therapeutic regimen for this 
condition. Furthermore, comparisons of therapeutic results obtained in dif- 
ferent case series, while always subject to bias in leukemia, are especially so in 
respect to the chronic lymphocytic form of the disease. The clinician who treats 
every case of chronic lymphocytic leukemia when first seen with a particular 
form of radiation or a new polyfunctional alkylating agent will report much 
better results than his colleague who withholds therapy in cases that do not 
appear to be progressive. 
Although the indications for therapy are more varied in chronic lymphocytic 
than in chronic granulocytic leukemia the available useful agents are fewer in 
the case of the lymphocytic form of the disease. They include radiation, certain 
alkylating agents of the nitrogen mustard type, and the adrenal cortical hormones. 
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In addition, splenectomy is sometimes of value in the presence of secondary 
hypersplenic manifestations, most often hemolytic anemia not readily controlled 
by the corticosteroids. 
When a patient suffering from chronic lymphocytic leukemia has conspicuous 
peripheral adenopathy or if the nodes appear to be enlarging, it is customary to 
treat with local x-radiation. The tumefaction, as a rule, responds readily to 
radiation administered in relatively small doses. It is the usual practice at the 
University of Michigan Hospital to treat each field, of about 10 by 10 cm. size, 
with single doses of 300 roentgens, although some radiologists employ even lower 
doses of 200 roentgens or less. More intensive therapy is rarely followed by 
superior effects and has the decided drawbacks of producing unnecessarily severe 
systemic reactions and, of greater importance, damaging skin and normal tissues 
and so limiting future use of an agent for which the indications may be repeated 
over many years. Total body x-radiation and internal irradiation with radio- 
active isotopes, notably P 32 for the treatment of chronic lymphocytic leukemia ,
have been completely replaced in the writer’s practice by the alkylating agents, 
triethylene melamine (TEM) and P&s (2-chloroethyl) aminophenylbutyric 
acid (chlorambucil, Leukeran). 
TEM, since the first reports of its use as a chemotherapeutic agent in 19.50, 
was the preferred drug for the treatment of chronic lymphocytic leukemia until 
the recent introduction of chlorambucil. Patients suffering from anemia, throm- 
bocytopenia, hypermetabolism, evidences of intra-abdominal or mediastinal 
adenopathy, visceral involvement, or extensive infiltration of marrow by leukemic 
lymphocytes may be benefited by either TEM or chlorambucil. The practice 
followed by some clinicians of employing drug therapy in essentially asympto- 
matic patients for “prophylactic” reasons or in the hope of obtaining some sub- 
jective benefit has not been adopted by the writer. 
TEM is a highly potent agent capable of producing profound marrow de- 
pression. Furthermore, the uncertainties of absorption when taken orally and 
the variable individual responsiveness to its myelosuppressive action increase 
the need for cautious administration. It is our practice to give 2.5 mg. by mouth, 
2 hours before breakfast with 2.0 Gm. of sodium bicarbonate for 1, 2, or 3 con- 
secutive days, depending on the amount of leukemic cell proliferation as esti- 
mated by the leukocyte count, and the degrees of adenopathy, splenomegaly, 
and bone marrow involvement. No further medication is given for 4 weeks, 
when another dose of 2.5 mg. is usually administered. Some patients receive 
2.5 mg. every 4 weeks for long periods as maintenance therapy. In others, 
treatment may be interrupted for an indefinite time. In general, maintenance 
therapy with TEM is difficult to establish in chronic lymphocytic leukemia. 
Chlorambucil, introduced as a therapeutic agent in malignant lymphoma, 
in 1953, by Galton and associates,24 is given with greater safety than TEM, but 
overdosage with this drug may be followed by myeloid depression, which occurs 
gradually and is readily reversible on discontinuing the medication.25 The 
usual initial dose range, based on body weight, is 0.1 to 0.2 mg. per kilogram per 
day. If maintenance therapy is planned, a daily dose of 2.0 to 4.0 mg. is usually 
well tolerated. In the series reported by Doan and associates,26 the initial dose 
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of chlorambucil in most patients with chronic lymphocytic leukemia was 0.2 
mg. per kilogram per day for 3 to 4 weeks. This was usually followed by a 
maintenance dose of 2 to 6 mg. daily or triweekly. 
It is not yet possible to evaluate the place of chlorambucil with respect to 
length of remissions or survival in chronic lymphocytic leukemia. However, 
experience gained in treating 18 patients with this disease for periods up to 24 
months at the Simpson Memorial Institute strongly indicates that except for 
ease of administration and dosage control chlorambucil has no therapeutic ad- 
vantages over TEM. Those patients exhibiting minimal or moderate activity 
of their disease are greatly benefited; those with advanced disease may have 
some suppression of leukemic cell growth and so derive some palliation. 
ADRENAL CORTICAL HORMONES IN CHRONIC LEUKEMIA 
The adrenal cortical hormones occupy a limited but well-defined place in 
the management of chronic leukemia. Granulocytic leukemia almost always 
manifests an adverse response to these agents, whereas in lymphocytic leukemia 
their administration may be followed by a fall in the leukocyte count and re- 
gression of adenopathy. These effects, however, are short-lived and the greatest 
usefulness of the adrenal cortical hormones is in the treatment of symptomatic 
hemolytic anemia and thrombocytopenic purpura. These manifestations of 
“hypersplenism” occur in about 10 per cent of patients with chronic lympho- 
cytic leukemia as well as in some cases of leukemic lymphosarcoma and malignant 
reticuloendotheliosis.27 
Initial adrenal steroid therapy as practiced by the writer is usually carried 
out with prednisone or prednisolone by employing doses of 15 mg. every 6 hours, 
given simultaneously with potassium chloride 0.5 Gm. and a suitable antacid. 
The diet should be low in salt but need not be severely restricted. After one 
week of high dosage the amount of the drug is gradually reduced until, in most 
cases, 5 mg. is taken every 8 hours. In some patients hemolysis or severe throm- 
bocytopenia may be prevented by 5 mg. of prednisone or prednisolone taken 
every 12 hours. 
Other indications for adrenal steroid therapy in chronic lymphocytic leu- 
kemia occur in advanced stages of the disease, when profound weakness, anorexia, 
emaciation, and bleeding develop in association with almost complete replacement 
of normal myeloid elements by leukemic lymphocytes. In these situations con- 
tinued administration of relatively small doses of the adrenal cortical hormones 
may be beneficial. 
ANTIBIOTIC AND BLOOD TRANSFUSION THERAPY IN CHRONIC LEUKEMIA 
Much of the improved outlook for patients with chronic leukemia, especially 
for those with the lymphocytic form of the disease, is attributable to the sup- 
portive measures which are now available. At the first sign of systemic infection, 
frequently pneumonitis, it is advisable to administer penicillin intramuscularly, 
400,000 units every 12 hours, and streptomycin 0.5 Gm. every 6 hours, after 
obtaining cultures for antibiotic sensitivity tests. 
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Since even minor surgical procedures, including dental extractions, are 
associated with increased risk of local infection, the prophylactic use of a broad- 
spectrum antibiotic in combination with penicillin is advocated in such situations. 
In spite of well-defined indications for their employment in special circum- 
stances, most patients having chronic leukemia do not require blood transfusions 
until the terminal phase of their illness. When the status of the disease is well 
differentiated at the time treatment is begun, the erythroid values may be ex- 
pected to improve with specific therapy, and transfusions should be withheld 
unless the anemia is so severe as to produce symptoms with slight activity. 
Patients who are able to maintain their hemoglobin and packed cell volume levels 
at, or above, 10 Gm. and 30 per cent, respectively, do not require transfusions, 
and the temporary rises obtained by the administration of blood are of no real 
benefit to them. 
Transfusions have a place as adjunct therapy in the management of patients 
with chronic leukemia when the following objectives apply. 
1. Improvement of hemoglobin levels in those patients who are severely 
anemic at the time of institution of specific therapy. 
2. Maintenance of hemoglobin values at levels sufficiently high to prevent 
or minimize angina1 symptoms in those patients having relative coronary arterial 
insufficiency. 
3. Replacement of blood lost by hemorrhage. 
4. Control of bleeding. If hemorrhage is due to secondary “hypersplenic” 
thrombocytopenia, or if the bleeding is from a local site, transfusions of fresh 
whole blood may tide the patient over until the hemorrhage may be arrested by 
other means. For this purpose transfusions of resuspended platelet concen- 
trates, which now have limited availability, are preferable to exclusive dependence 
on whole blood. 
5. Counteraction of the effects on circulating erythroid values of secondary 
hemolysis until the condition may be controlled by specific measures. 
6. Partial correction of anemia in patients who have received overdosage 
of radiation or a chemotherapeutic agent. Although such eventualities should 
generally be avoidable by judicious selection of dosage and adequate interval 
observation, an occasional patient will react in an unexpected manner to initial 
therapy. More often, the distinction between maximum maintenance control 
and overtreatment may be so fine that in attempting to manipulate dosages 
to achieve the former, myeloid depression may be produced. We have observed 
this development most frequently with triethylene melamine in chronic lympho- 
cytic leukemia, but it has also been encountered rarely in patients having chronic 
granulocytic leukemia receiving either TEM or Myleran. Permanent ill effects 
of such overtreatment, when recognized early, have not occurred in our experience. 
7. Maintenance of erythroid values at tolerable levels in patients having 
advanced disease in whose marrow there is little remaining erythropoiesis. Such 
an outcome is not infrequent in chronic lymphocytic leukemia, even in the pres- 
ence of relatively good preservation of function of other organs. Two or three 
500 C.C. transfusions at monthly intervals are usually sufficient to maintain 
hemoglobin levels between 7 and 10 Gm. per 100 c.c., sometimes for a year or 
longer. 
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SUMMARY 
One thousand one hundred and seventy-nine cases of leukemia in persons 
over the age of 13 years seen at the Simpson Memorial Institute of the University 
of Michigan, from 1927 through 1956, have been reviewed. 
Seven hundred and thirty-four cases were classified as chronic and 455 as 
acute. 
The ratio of acute to chronic cases has shown a steady rise during the period 
studied so that the incidence of acute leukemia seems to be definitely increasing. 
The incidence of all forms of chronic leukemia is probably increasing but 
the nature of the case selection in the present study precludes proof of this thesis. 
There is no evidence afforded by this series of cases that the relative fre- 
quency of chronic granulocytic leukemia and chronic lymphocytic leukemia is 
changing, or that there has been any change in sex distribution or age incidence 
in the chronic leukemias. 
Ionizing radiation continues to be the standard of reference when new forms 
of treatment for chronic leukemia are proposed, and it has not been conclusively 
demonstrated that survival times are increased or even equaled by the use of 
drugs in comparison with x-radiation or radioactive phosphorus. Nevertheless, 
chemotherapy has largely supplanted radiation in the treatment of chronic 
granulocytic and lymphocytic leukemias in this institution in recent years. With 
the passage of time and the enlargement of experience, the use of these thera- 
peutic modalities has received increasing justification. 
The alkylating agents, Myleran, TEM, and chlorambucil, are the preferred 
forms of drug therapy for chronic leukemias. 
There is no evidence of a qualitative difference in biologic actions of these 
compounds, but there are quantitative variations which affect dosages, ab- 
sorption rates, duration of effects, and likelihood of severe myeloid depression. 
At the present time, because of advantages of administration, dosage control, 
and relative safety, Myleran is generally preferred in chronic granulocytic leu- 
kemia and chlorambucil in chronic lymphocytic leukemia. 
Continuous drug administration on individually determined maintenance 
dosage has proved superior to intermittent courses of therapy in controlling 
activity of the leukemic process. 
Colcemide may be useful in some cases of advanced proliferative granulocytic 
leukemia and the antimetabolite, 6-mercaptopurine (Purinethol) may be em- 
ployed in these situations. 
The adrenal cortical steroids are mainly of value in controlling secondary 
hemolysis and thrombocytopenia which occur in some patients with chronic 
lymphocytic leukemia and malignant reticuloendotheliosis. When satisfactory 
control of these manifestations cannot be established or maintained by hormonal 
therapy, splenectomy may be effective. 
REFERENCES 
1. Third, Fourth and Fifth Reports of the Committee for Clarification of the Nomenclature of 
Cells and Diseases of the Blood and Blood-forming Organs, Am. J. Clin. Path. 20:562, 
19.50. 
420 RETHELL 
March, H. C.: Leukemia in Radiologists, Am. J. M. SC. 220:282, 1950. 
Brown, W. M. C., and Abbatt, J. D.: The Incidence of Leukaemia in Ankylosing Spondy- 
litis Treated With X-rays, Lancet 1:1283, 1955. 









Sacks,ly47S., and Seeman, I.: A Statistical Study of Mortality From Leukemia, Blood 2:1, 
Bethell, F. H.: Lymphogenous (Lymphatic) Leukemia: Diagnostic., Prognostic, and Thera- 
peutic Considerations Based on an Analysis of its Morphologrc and Clinical Variants, 
J.A.M.A. 118:95, 1942. 
Bethell, F. H. : Leukemia, The Relative Incidence of Its Various Forms, and Their Response 
to Radiation Therapy, Ann. Int. Med. 18:7.57, 1943. 
Shimkin, M. B., Mettier, S. R., and Bierman, H. R.: Myelocytic Leukemia: An Analysis 
of Incidence, Distribution and Fatality, Ann. Int. Med. 35:194, 19.51. 
Gauld, W. R., Innes, J., and Robson, H. N.: A Survey of 647 Cases of Leukaemia, 1938 
1951, Brit. M. J. 1585, 1953. 
Tivey, H.: The Prognosis for Survival in Chronic Granulocytic and Lymphocytic Leukemia, 
Am. J. Roentgenol. 72:68, 1954. 
Osgood, E. E.: Titrated, Regularly Spaced Radioactive Phosphorus or Spray Roentgen 
Therapy of Leukemias, A.M.A. Arch. Int. Med. 87:329, 1051. 
Paterson, E., Haddow, A., Ap Thomas, I., and Watkinson, J. M.: Leukaemia Treated With 
Urethane Compared With Deep X-ray Therapy, Lancet 1:677, 1946. 
Gilman, A., and Philips, F. S.: The Biological Actrons and Therapeutic Applications of 
the B-Chloroethyl Amines and Sulfides, Science 103:409, 1946. 
Rhoads, C. P., Karnofsky, D.A., Burchenal, J. H., and Craver, L. F.: Triethylene Melamine 





Bond, W. H., Rohn, R. J., Dyke, R. W., and Fonts, P. J.: Clinical Use of 
Melamine: Report of Seventy-Five Cases, Arch. Int. Med. 91:602, 1953. 
Triethylene 
Haddow, A., and Timmis, G. M.: 
1953. 
Myleran in Chronic Myeloid Leukaemia, Lancet 1:207, 
Rhoads, C. P.: Summary of Conference on Comparative Clinical and Biological Effects of 
Alkylating Agents, New York, N. Y. March 28-30, 1957, Ann. New York Acad. SC. 
(in press). 
18. Galton, D. A. G.: Busulphan (Myleran): Summary of Clinical Work, in Comparative 
Clinical and Biological Effects of Alkylating Agents, Ann. New York Acad. SC. 
(in press) _ 
19. 
20. 
Osgooi9$ E., and Seaman, A. J.: Treatment of Chronic Leukemias, Radiology 64:373, 
Moeschlin!‘S., Meyer, H., and Lichtman, A.: Ein Neues Colchicum-Nebenalkaloid (Deme- 






Moeschlin, S.: Round Table Discussion on Therapy, in the Leukemias: Etiology, Patho- 
physiology, and Treatment, Ed. by Rebuck, J. W., Bethell, F. H., and Monto, R. W., 
New York, 1957, Academic Press, Inc. 
Bethell, F. H.: Proceedings of Second Conference on Folic Acid Antagonists in Leukemia 
Treatment, Blood 7:119, 1952. 
Mines, R. W., and Rhoads, C. P. (editors): 
60:183, 1954. 
6-Mercaptopurine, Ann. New York Acad. SC. 
Galton, D. A. G., Israels, L. G., Nabarro, J. D. N., and Till, M.: Clinical Trials of P-(di- 
2- chloroethylamino)-Phenylbutyric Acid (CB 1348) in Malignant Lymphoma, Brit. 
M. J. 2:1172, 19.55. 
25. Altman, S. J,, Haut, A., Cartwright, G. E., and Wintrobe, M. M.: Early Experience With 
P-NN-Dl-2-Chloroethylaminophenylbutyric Acid (“CB 1348”), a New Chemothera- 




Doan, C. A., Wiseman, B. K., and Bouroncle, B.: Clinical Evaluation of CB-1348 in Leuke- 
mias and Lymphomas, in Comparative Clinical and Biological Effects of Alkylating 
Agents, Ann. New York Acad. SC. (in press). 
Dameshek,. W. : Round Table Discussion on Therapy, in The Leukemias: Etiology, Patho- 
physiology, and Treatment, Ed. by Rebuck, J. W., Bethell, F. H., and Monto, R. W., 
New York, 1957, Academic Press, Inc. 
J. Chron. IXs. 
October, 1957 
